Exhibit 99.2

              Greatbatch Provides Preliminary Financial
                          Estimates for 2008


    CLARENCE, N.Y.--(BUSINESS WIRE)--November 28, 2007--Greatbatch,
Inc. (NYSE: GB) recently presented at Investor Conferences in New York
City where Thomas J. Hook, President and Chief Executive Officer,
described the Company's expanded strategic direction, which is based
on growth through Innovation, Investment and Acquisition. These
presentations can be accessed on the Company's website at
www.greatbatch.com. The key takeaways from the Conferences are
described below:

    Over the past 3 years, Greatbatch has delivered strong revenue and
profitability growth. Initiatives focused on key customer
opportunities, and operational consolidations of multiple locations
into new manufacturing facilities, have delivered growth above the
rates of the underlying markets. Both medical & commercial business
segments have significant opportunities for further improvement but
CRM industry concentration remains a risk given the market dynamics.
Greatbatch's strategic plan encompasses the continued growth in the
CRM market, but also enhances these plans with aggressive investment &
acquisition initiatives to diversify the company in implantable
medical markets and specialty commercial power applications.
Technology will remain the key focal point for each of the market
opportunities. The acquisitions of Biomec, Enpath, Quan Emerteq &
Precimed in medical and IntelliSensing & EAC in commercial have
positioned Greatbatch more broadly within the strategic markets
served. The execution of these strategic initiatives has established
Greatbatch as a leader in four market verticals; CRM,
Neurostimulation, Vascular, Orthopedics and Specialty Commercial
Power. Innovation and investment initiatives have also contributed
critical technologies to Greatbatch's product portfolio. Following
this acquisition period, Greatbatch has sound financials, including
continued revenue & profitability growth, strong cash flow generation
and a conservative capitalization structure. 2008 will commence a
period of concentrated integration activities for the various
acquisitions & investments and will dovetail nicely into the current
Greatbatch initiatives and leadership team. Several recognized
industry leaders have joined the Greatbatch executive team following
the acquisitions. The new leaders will provide Greatbatch the
experience and balance to successfully grow and integrate multiple
businesses. The combined Greatbatch management team is highly
motivated to deliver revenue & profit growth and is enthusiastic about
the future opportunities.

    Based on the anticipated completion of the announced acquisitions,
the Company provided preliminary 2008 financial estimates, as follows:

    2008 Preliminary Financial Estimates

    --  Sales $500 - $550 Million

    --  Adjusted Operating Income Margin 11% - 13%

    --  Adjusted EBITDA Margin 21% - 23%

    --  Targeting Improvements in Operating Margin of 200 Basis Points
        Per Year for the Next Three Years

    Note: Adjusted Operating and EBITDA exclude the impact of the
acquisition related charges, such as in-process research development
and integration costs. This financial information is a preliminary
estimate based upon the closing of the recently announced Precimed
acquisition in early 2008. These estimates shown are subject to change
based upon the results of purchase price accounting, which will not be
finalized until 2008. Additionally, these estimates exclude
integration costs and anticipated synergies, which will not be fully
determined until the first quarter of 2008.

    Forward-Looking Statements

    Some of the statements in this press release and other written and
oral statements made from time to time by the Company and its
representatives are "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and section 21E
of the Securities Exchange Act of 1934, as amended, and involve a
number of risks and uncertainties. These statements can be identified
by terminology such as "may," "will," "should," "could," "expects,"
"intends," "plans," "anticipates," "believes," "estimates,"
"predicts," "potential" or "continue," or the negative of these terms
or other comparable terminology. These statements are based on the
Company's current expectations. The Company's actual results could
differ materially from those stated or implied in such forward-looking
statements. Risks and uncertainties that could cause actual results to
differ materially from those stated or implied by such forward-looking
statements include, among others, the following matters affecting the
Company: dependence upon a limited number of customers; customer
ordering patterns; product obsolescence; inability to market current
or future products; pricing pressure from customers; our ability to
timely and successfully implement our cost reduction and plant
consolidation initiatives; reliance on third party suppliers for raw
materials, products and subcomponents; fluctuating operating results;
inability to maintain high quality standards for our products;
challenges to our intellectual property rights; product liability
claims; inability to successfully consummate and integrate
acquisitions; unsuccessful expansion into new markets; competition;
inability to obtain licenses to key technology; regulatory changes or
consolidation in the healthcare industry; and other risks and
uncertainties described in the Company's Annual Report on Form 10-K
and in other periodic filings with the Securities and Exchange
Commission. The Company assumes no obligation to update
forward-looking information in this press release whether to reflect
changed assumptions, the occurrence of unanticipated events or changes
in future operating results, financial conditions or prospects, or
otherwise.

    About Greatbatch, Inc.

    Greatbatch, Inc. (NYSE: GB) is a leading developer and
manufacturer of critical components used in medical devices for the
cardiac rhythm management, neurostimulation, vascular and
interventional radiology markets. Additionally, Electrochem Commercial
Power, a subsidiary of Greatbatch, is a world leader in the design and
manufacture of electrochemical cells, battery packs and wireless
sensors for demanding applications such as oil and gas exploration,
pipeline inspection, military, asset tracking, oceanography, external
medical and seismic surveying. Additional information about the
Company is available at www.greatbatch.com.


    CONTACT: Greatbatch, Inc.
             Anthony W. Borowicz, 716-759-5809
             Treasurer and Director, Investor Relations
             tborowicz@greatbatch.com